Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by trade2win2on Jun 07, 2012 3:19pm
319 Views
Post# 19990526

News-

News-

Well now we know they are fast tracking this consolidation to be completed before test results..

Santa Maria Petroleum Inc.: Implementation of Share Consolidation and Name Change

ccnm

CALGARY, ALBERTA--(Marketwire - June 7, 2012) - Santa Maria Petroleum Inc. (formerly Quetzal Energy Ltd.) (The "Company") (TSX VENTURE:QEI) is pleased to announce that it has filed articles of amendment to implement the consolidation of its common shares ("Common Shares") on the basis of one post-consolidation Common Share for every 10 pre-consolidation Common Shares and to change the name of the Company from "Quetzal Energy Ltd." to "Santa Maria Petroleum Inc."

The Company expects that the post-consolidation Common Shares will begin trading on the TSX Venture Exchange under the new symbol "SMQ" on or about June 11, 2012.

To receive certificates representing post-consolidation Common Shares, registered shareholders of the Company (the "Shareholders") should follow the instructions set out in the letter of transmittal and send their certificates representing pre-consolidation Common Shares, together with a properly executed letter of transmittal, to Equity Financial Trust Company, the registrar and transfer agent of the Company. Letters of transmittal with respect to the consolidation, copies of which are available on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com, were mailed to all registered Shareholders. Beneficial Shareholders should contact their nominees with any questions regarding the procedures applicable to them.

About Santa Maria Petroleum Inc.

Bullboard Posts